Collect from /

Excellent Solution For Your Business

f the clinical trial on March 27 have ended centralized medical observation and are in good condition. The second phase will recruit 500 volunteers and introduce the placebo control group to further evalua

te the immunogenicity and safety of the vaccine. As of 5 p.m. on April 13, 273 volunteers had been vaccinated. An inactivated vaccine candidate developed by the Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Sinopharm) and the Wuhan Institute of Virology under the Chinese Academy of Sciences was approved for clinical trials on April 12, Wu said. Another inactivated vaccine candidate developed by Sinovac Research and Development Co., Ltd., a company based in Beijing, was approved on April 13, he added. Using killed pathogenic microorganisms to enhance the immunogenicity, inactivated vaccines have advantages of mature production process, controllable quality standards and wide protecti

on range, according to Wang Junzhi, an academician with the Chinese Academy of Engineering. To produce the vaccine, researchers cultivated live viruses on a large scale in P3 laboratories, which have relatively high biosafety standards, Wang said. Experts have been invited to give whole-process direction in the preclinical animal experiments of the vaccines, including acute toxicity experiments, repeated toxicity experiments and immunogenicity experiments, he said. Sample vaccines for clinical trials have passed i

nspections by the Food and Drug Administrati

We'll Make Sure Template Works For You

on and the National Institutes for Food and Drug Control, he added. China has laid a solid foundation for research into inactivated vaccines over recent years. Inactivated vaccines have been widely used

to fight hepatitis A, influenza, hand-foot-and-mouth disease and poliomyelitis, he said. The safety and effectiveness of inactivated vaccines can be judged by internationally accepted standards, Wu said. FIVE APPROACHES TO VACCINES Wu said China adopted five technological approaches to develop COVID-19 vaccines, including inactivated vaccines, recombinant protein vaccines, adenovirus vector vaccines, nucleic acid vaccines and vaccines using attenuated influenza viruses as vectors. Aside from the adenovirus vector vaccine and inactivated vaccine, vaccines of other technical routes are also advancing rapidly. The strains have been constructed and quality inspec

tion methods have been set up for the vaccine using attenuated influenza viruses. Pilot production, animal poison attack experiments and safety evaluation experiments will be carried out in the same period, according to Wu. The recombinant protein vaccine has completed the construction of virus species, and is carrying out the genetic stability inspection, animal experiments and safety evaluation, Wu said. The nucleic acid vaccine has also entered the research stage of animal experiments and safety evaluation, and

the preparation and quality inspection of sa

mples for clinical trials are carried out simultaneously, he said. These vaccine

Image Gallery

Services Overview

candidates are expected to apply for clinical trials in April and May, he said. China has accelerated the approval procedures for COVID-19 vaccines that have demonstrated their safety

Contact Us

and efficacy. The seamless connection between research and approval is the major reason behind the fast development of vaccin

es, according to Wang. Stressing safety as a priority, Wang said clinical trials of a vaccine usually undergo three phases. The first phase usually enrolls dozens of volunteers to test the safety of the vaccine and the human body's tolerance to different doses. The second phase wil

    涛嘉食品加工?? 食品加工厂涛?? 涛嘉矿产贸易 餐饮集团涛嘉 涛嘉餐饮集团 娱乐公司涛嘉 涛嘉娱乐公司 技术公司涛??